KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Net Margin (2016 - 2025)

Nektar Therapeutics has reported Net Margin over the past 16 years, most recently at 159.27% for Q4 2025.

  • Quarterly results put Net Margin at 159.27% for Q4 2025, down 18416.0% from a year ago — trailing twelve months through Dec 2025 was 281.27% (down 16040.0% YoY), and the annual figure for FY2025 was 281.27%, down 16040.0%.
  • Net Margin for Q4 2025 was 159.27% at Nektar Therapeutics, up from 296.76% in the prior quarter.
  • Over the last five years, Net Margin for NKTR hit a ceiling of 974.58% in Q4 2023 and a floor of 736.94% in Q2 2022.
  • Median Net Margin over the past 5 years was 277.74% (2025), compared with a mean of 277.62%.
  • Biggest five-year swings in Net Margin: skyrocketed 123331bps in 2023 and later plummeted -94969bps in 2024.
  • Nektar Therapeutics' Net Margin stood at 587.42% in 2021, then skyrocketed by 56bps to 258.73% in 2022, then soared by 477bps to 974.58% in 2023, then plummeted by -97bps to 24.89% in 2024, then crashed by -740bps to 159.27% in 2025.
  • The last three reported values for Net Margin were 159.27% (Q4 2025), 296.76% (Q3 2025), and 350.85% (Q2 2025) per Business Quant data.